XML 50 R30.htm IDEA: XBRL DOCUMENT v3.26.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2025
Income Tax Disclosure [Abstract]  
Schedule of Income Tax (Benefit)/Provision

The Company’s income tax (benefit)/provision is as follows for the years ended December 31, 2025 and 2024:

  

   2025   2024 
Current  $-   $- 
Deferred   (1,606,119)   (5,446,000)
Change in Valuation Allowance   1,606,119    5,446,000 
Income Tax Benefit  $-   $- 
Schedule of Components of Loss Before Income Taxes

The following table shows the components of loss before income taxes and the related income tax expense / (benefit):

   2025   2024 
Loss before income taxes          
U.S. operations  $(11,627,122)  $(23,359,334)
Current income tax expense / (benefit)          
U.S. federal   -    - 
U.S. state and local   -    - 
Total current income tax expense / (benefit)   -    - 
Deferred income tax expense / (benefit)          
U.S. federal   -    - 
U.S. state and local   -    - 
Total deferred income tax expense / (benefit)   -    - 
Total current income tax expense / (benefit)  $-   $- 
Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes

The reconciliation of income taxes using the statutory U.S. income tax rate and the benefit from income taxes for the years ended December 31, 2025 and 2024 are as follows:

  

   2025   2024 
         
Statutory U.S. Federal Income Tax Rate   (21.0)%   (21.0)%
State income taxes, net of U.S. Federal tax effect   (7.4)%   (7.5)%
Adjustment to deferred tax assets   7.0%   2.9%
Tax credits   (2.4)%   (1.6)%
Non-deductible expenses   2.3%   3.9%
Change in Valuation Allowance   17.7%   23.3%
Net   0.0%   0.0%
Schedule of Deferred Tax Assets and Related Valuation Allowances

The principal components of the deferred tax assets and liabilities, and related valuation allowances as of December 31, 2025 and 2024 are as follows:

  

   2025   2024 
         
Reserves and other  $1,421,000   $731,000 
Net operating loss carry-forwards   29,455,000    27,869,000 
Capitalized research and development   2,513,000    3,894,000 
Research and development tax credit   2,479,000    2,205,000 
Share-based compensation   1,877,000    1,430,000 
Valuation Allowance   (37,735,000)   (36,129,000)
Net deferred tax asset  $-   $-